uniQure (NASDAQ:QURE) Shares Down 3.5% – What’s Next?

uniQure (NASDAQ:QURE)’s stock price dropped 3.5% on Monday . The stock traded as low as $17.21 and last traded at $17.32. Approximately 85,917 shares traded hands during mid-day trading, a decline of 86% from the average daily volume of 603,523 shares. The stock had previously closed at $17.94.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Wells Fargo & Company upgraded uniQure from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 10th. Mizuho raised their target price on uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, December 19th. Raymond James raised uniQure from an “outperform” rating to a “strong-buy” rating and raised their target price for the stock from $20.00 to $52.00 in a research note on Tuesday, December 10th. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of uniQure in a research report on Tuesday, December 10th. Finally, Stifel Nicolaus lifted their target price on uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, December 16th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, uniQure presently has a consensus rating of “Moderate Buy” and an average target price of $33.88.

uniQure Price Performance

The company has a market capitalization of $889.07 million, a price-to-earnings ratio of -3.68 and a beta of 0.41. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The company has a 50 day simple moving average of $10.38 and a 200 day simple moving average of $7.64.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The business had revenue of $2.29 million during the quarter, compared to analyst estimates of $2.73 million. As a group, research analysts predict that uniQure will post -3.82 EPS for the current year.

Insider Buying and Selling at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the transaction, the chief executive officer now owns 597,915 shares of the company’s stock, valued at $4,562,091.45. This trade represents a 0.57 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 4.74% of the stock is owned by insiders.

Institutional Trading of uniQure

Large investors have recently added to or reduced their stakes in the business. RTW Investments LP acquired a new stake in uniQure in the 3rd quarter valued at approximately $49,000. China Universal Asset Management Co. Ltd. increased its position in shares of uniQure by 57.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 3,663 shares during the period. Atria Investments Inc acquired a new position in shares of uniQure during the 3rd quarter valued at $53,000. Quarry LP acquired a new position in shares of uniQure in the 3rd quarter worth $58,000. Finally, Vanguard Personalized Indexing Management LLC grew its holdings in shares of uniQure by 21.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 2,306 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.